Mingxiang Liao

1.6k total citations
46 papers, 1.2k citations indexed

About

Mingxiang Liao is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Mingxiang Liao has authored 46 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 13 papers in Molecular Biology and 11 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Mingxiang Liao's work include Drug Transport and Resistance Mechanisms (19 papers), Pharmacological Effects and Toxicity Studies (11 papers) and Pharmacogenetics and Drug Metabolism (8 papers). Mingxiang Liao is often cited by papers focused on Drug Transport and Resistance Mechanisms (19 papers), Pharmacological Effects and Toxicity Studies (11 papers) and Pharmacogenetics and Drug Metabolism (8 papers). Mingxiang Liao collaborates with scholars based in United States, China and Japan. Mingxiang Liao's co-authors include Maria Almira Correia, Xiaoyan Chu, Yurong Lai, Magang Shou, Karen Rowland Yeo, Jiansong Yang, Masoud Jamei, Amin Rostami‐Hodjegan, Geoffrey T. Tucker and Guangqing Xiao and has published in prestigious journals such as Journal of Biological Chemistry, Analytical Chemistry and Cancer Research.

In The Last Decade

Mingxiang Liao

45 papers receiving 1.2k citations

Peers

Countries citing papers authored by Mingxiang Liao

Since Specialization

Citations

This map shows the geographic impact of Mingxiang Liao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mingxiang Liao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mingxiang Liao more than expected).

Fields of papers citing papers by Mingxiang Liao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mingxiang Liao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mingxiang Liao. The network helps show where Mingxiang Liao may publish in the future.

Co-authorship network of co-authors of Mingxiang Liao

This figure shows the co-authorship network connecting the top 25 collaborators of Mingxiang Liao. A scholar is included among the top collaborators of Mingxiang Liao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mingxiang Liao. Mingxiang Liao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	DynRefer: Delving into Region-level Multimodal Tasks via Dynamic Resolution 2025 ·Yuzhong Zhao, (unknown), (unknown), Mingxiang Liao, Chen Gong, Qixiang Ye, Fang Wan	0
2	Optimization of Grassland Carrying Capacity with Grass Quality Indicators Through GF5B Hyperspectral Images 2024 ·Remote Sensing ·Xuejun Cheng, Mingxiang Liao, Shuangyin Zhang, Siying Wang, Yiyun Chen, Teng Fei	1
3	Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib 2022 ·Clinical Pharmacokinetics ·Mingxiang Liao, (unknown), Heidi Giordano, Thomas C. Harding, Lara Maloney, Andrew D. Simmons, Jim Xiao	8
4	Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment 2021 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), Monika Tomaszewska‐Kiecana, Rodryg Ramlau, (unknown), Yvette Drew, Rafał Dziadziuszko, Milada Zemanová, (unknown), (unknown), (unknown), Mingxiang Liao, Jim Xiao	11
5	A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors 2021 ·Cancer Chemotherapy and Pharmacology ·Mingxiang Liao, Krzysztof Jeziorski, Monika Tomaszewska‐Kiecana, István Láng, Marek Jasiówka, (unknown), (unknown), Rodryg Ramlau, (unknown), J. Jack Lee, Sarah Edwards, (unknown), (unknown), (unknown), Jim Xiao	9
6	Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach 2020 ·Drug Metabolism and Disposition ·Vineet Kumar, (unknown), Kazuya Ishida, Laurent Salphati, Cornelis E. C. A. Hop, Christopher Rowbottom, Guangqing Xiao, Yurong Lai, Anita Mathias, Xiaoyan Chu, W. Griffith Humphreys, Mingxiang Liao, (unknown), (unknown), Scott Heyward, Jashvant D. Unadkat	27
7	Positron Emission Tomography Imaging of [¹¹C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A 2019 ·Clinical Pharmacology & Therapeutics ·Sarah Billington, Steven C. Shoner, Scott D. Lee, Kindra Clark‐Snustad, (unknown), David H. Lewis, Mark Muzi, (unknown), Jean Lee, Tot Bui Nguyen, Vineet Kumar, Kazuya Ishida, Laigao Chen, Xiaoyan Chu, Yurong Lai, Laurent Salphati, Cornelis E. C. A. Hop, Guangqing Xiao, Mingxiang Liao, Jashvant D. Unadkat	50
8	Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors 2019 ·Investigational New Drugs ·Mingxiang Liao, Simon P. Watkins, (unknown), Jeff Isaacson, Jeff Etter, (unknown), Rong Fan, Li Shen, Abdul Mutlib, Vendel Kemény, Zsuzsanna Pápai, (unknown), Jim Xiao	29
9	A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation 2019 ·Drug Metabolism and Disposition ·Vineet Kumar, Laurent Salphati, Cornelis E. C. A. Hop, Guangqing Xiao, Yurong Lai, Anita Mathias, Xiaoyan Chu, W. Griffith Humphreys, Mingxiang Liao, Scott Heyward, Jashvant D. Unadkat	38
10	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium 2018 ·Clinical Pharmacology & Therapeutics ·Xiaoyan Chu, Mingxiang Liao, Hong Shen, Kenta Yoshida, Arik A. Zur, Vikram Arya, Aleksandra Galetin, Kathleen M. Giacomini, Imad Hanna, Hiroyuki Kusuhara, Yurong Lai, David Rodrigues, Yuichi Sugiyama, Maciej J. Zamek‐Gliszczynski, Lei Zhang	161
11	In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties 2017 ·Toxicological Sciences ·Robert W. Yucha, Kan He, Qin Shi, Lining Cai, (unknown), Cindy Q. Xia, Mingxiang Liao	23
12	Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling 2016 ·The AAPS Journal ·Andy Z. X. Zhu, (unknown), (unknown), (unknown), Mingxiang Liao, Cindy Q. Xia	23
13	Synthesis of a new inhibitor of breast cancer resistance protein with significantly improved pharmacokinetic profiles 2015 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), (unknown), Cindy Q. Xia, Mingxiang Liao, (unknown), Johnny Yang, (unknown), (unknown), Shimoga R. Prakash	14
14	Confidence Assessment of an Absorption Model Using Limited Solubility and Permeability Data for 21 Drugs within a Dynamic Physiologically-Based Pharmacokinetic Simulator 2015 ·Stewart C. Wang, Mingxiang Liao, Cindy Q. Xia	1
15	Culture Duration-, Donor-, and Medium-Dependent Changes in OATP1B3- Mediated Telmisartan Uptake in Human Hepatocytes 2014 ·Drug Metabolism Letters ·Qing Zhu, (unknown), Cindy Q. Xia, Qian Yang, (unknown), Albert P. Li, Mingxiang Liao	7
16	Ubiquitin-dependent Proteasomal Degradation of Human Liver Cytochrome P450 2E1 2011 ·Journal of Biological Chemistry ·(unknown), Shenheng Guan, (unknown), Dennis R. Koop, Yi Liu, Mingxiang Liao, Alma L. Burlingame, Maria Almira Correia	42
17	P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor 2010 ·Drug Metabolism Letters ·Johnny Yang, Mark Milton, Shaoxia Yu, Mingxiang Liao, Ning Liu, Jingtao Wu, Liang‐Shang Gan, Suresh K. Balani, Frank W. Lee, Shimoga R. Prakash, Cindy Q. Xia	43
18	Liver Cytochrome P450 3A Endoplasmic Reticulum-associated Degradation 2010 ·Journal of Biological Chemistry ·(unknown), Mingxiang Liao, Juan C. Engel, Maria Almira Correia	18
19	A Role for Protein Phosphorylation in Cytochrome P450 3A4 Ubiquitin-dependent Proteasomal Degradation 2008 ·Journal of Biological Chemistry ·Yong‐Qiang Wang, Mingxiang Liao, Nicholas Hoe, (unknown), Changhui Deng, Andrew N. Krutchinsky, Maria Almira Correia	41
20	The effect of chemical carcinogenesis on rat glutathione S-transferase P1 gene transcriptional regulation 2001 ·Molecular Biology Reports ·Dongyuan Liu, Mingxiang Liao, Jin Zuo, W. David Henner, Fude Fang	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact